Savvy Trades and Investments

[2morrowsGains]

SRTS...Sensus Healthcare Receives Regulatory Approval to Sell the SRT-100™ in China for the Treatment and Prevention of Keloids

BOCA RATON, Fla., July 26, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that the SRT-100™ has been cleared by the China Food and Drug Administration (CFDA) to treat and prevent keloids. China accounts for more than 20% of the world's patient population.

The Company's partner in China is Chindex Medical Limited, a wholly owned subsidiary of Fosun Pharma International. Chindex Medical plans to launch the SRT-100 for the treatment of keloids into the market during the fourth quarter of 2017, with a focus on preventing and treating keloids associated with Cesarean sections (C-sections). Chindex Medical has been selling the SRT-100 in China for the treatment of non-melanoma skin cancer since 2014.

"CFDA clearance of the SRT-100 for the treatment and prevention of keloids is an important milestone for Sensus, and a step forward for healthcare in China, especially women's health," commented Joe Sardano, chief executive officer of Sensus Healthcare. "According to a study in 2010 by the World Health Organization, 46.2% of Chinese babies were delivered via C-section. Additionally, although the exact numbers are not known, Asians have the highest incidence of post-surgical keloid scar formation. With the relaxing of China's one-child policy in 2015, the prevention of keloids that form over the surgical scar following a first C-section will lessen complications of a second C-section. We believe the SRT-100 will be a major force in preventing these keloids from forming."

Chindex Medical will launch the SRT-100 for the treatment and prevention of keloids at the International Congress of the Dermatologic & Aesthetic Surgery International League in Shanghai, taking place October 24-28. Several dermatologists from the U.S. will be in attendance to train and educate Chinese physicians during a very large workshop dedicated to SRT and a session on scar treatments.

William Wang, chief executive officer of Chindex Medical said, "We are very pleased by the CFDA's decision to grant permission to treat keloids with SRT. This is another example of continued efforts by Chindex Medical Ltd to bring cost effective solutions to our healthcare system. Our doctors now have a very important tool in a proven technology like SRT to remedy the keloids that impact millions of our citizens."

About Keloids
Keloids are benign fibrous tissue formed at the site of a scar or injury to the skin. Although keloids have been known to form in all races, they are seen most frequently among those of African, Latin and Asian descent. Surgery and other treatment methods may reduce the size of the keloid, but with a reoccurrence rate of 90%, the current treatment methods are not a permanent solution. Sensus Healthcare's SRT device is a safe alternative in treating existing keloid conditions and is proven to be most effective for reducing the recurrence of keloids when combined with excision surgery.
http://www.investorpoint.com/stock/SRTS-Sensus%20Healthcare%20Inc./news/7327642191672419/